Mga Batayang Estadistika
| CIK | 1875091 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeuroSense Therapeutics Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
Exhibit 99.1 NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass., September 4, 2025, - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseas |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzli |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| September 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 4, 2025, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subj |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 21, 2025 |
Exhibit 99.1 11 Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 25, 2025 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual General Meeting of Shareholders (the “Meeting”), of NeuroSense Therapeutics Ltd. (the “Company”), to be held at 11:00 a.m. (Israel time) on September 25, 2025 |
|
| August 21, 2025 |
Exhibit 99.2 NEUROSENSE THERAPEUTICS LTD. 11 HAMENOFIM STREET BUILDING B HERZLIYA 4672562 ISRAEL SCAN TO VIEW MATERIALS & VOTE Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on September 24, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to crea |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 15, 2025 |
Registration No. As filed with the Securities and Exchange Commission on August 15, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact name of registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| August 15, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 NEUROSENSE THERAPEUTICS LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025. As filed with the Securities and Exchange Commission on August 15, 2025. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025. As filed with the Securities and Exchange Commission on August 15, 2025. Registration No. 333-283338 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s |
|
| August 8, 2025 |
NeuroSense Therapeutics Ltd. Up to $14,203,914 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-269306 AMENDMENT NO. 2 TO PROSPECTUS SUPPLEMENT DATED AUGUST 16, 2024 (To prospectus dated January 30, 2023) NeuroSense Therapeutics Ltd. Up to $14,203,914 Ordinary Shares This Amendment No. 2 (the “Amendment”) amends and supplements the information in the prospectus supplement, dated August 16, 2024, as supplemented by the Amendment No. 1 to t |
|
| August 1, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in in conformity with United States of America, or U.S. GAAP. Unless otherwise in |
|
| August 1, 2025 |
The accompanying notes are an integral part of the condensed interim financial statements. Exhibit 99.2 NeuroSense Therapeutics Ltd. Condensed Interim Unaudited balance sheets U.S. dollars in thousands June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalent 666 3,378 Other receivables 847 989 Restricted deposit 43 35 Total current assets 1,556 4,402 Non-current assets: Property, plant and equipment, net 63 66 Operating right of use assets 42 84 Restricted deposit |
|
| August 1, 2025 |
NeuroSense Provides Business Update and Progress for the First Half of 2025 Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2025 CAMBRIDGE, Mass., August 1, 2025 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and financial results of th |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996183 ( |
|
| May 7, 2025 |
Exhibit 99.1 NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ - Neu |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| April 24, 2025 |
Exhibit 99.1 NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass., April 24, |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996183 |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025. As filed with the Securities and Exchange Commission on April 11, 2025. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s n |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025. As filed with the Securities and Exchange Commission on April 11, 2025. Registration No. 333-283338 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s n |
|
| April 7, 2025 |
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates Exhibit 99.1 NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates ● Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline ● Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization ● Phase 3 study design for PrimeC in ALS aligned |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996183 |
|
| April 7, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-262480) on Form S-8 and (No. 333-269306, No. 333-284051, 333-283656 and 333-260338) on Form F-3 of our report dated April 7, 2025, with respect to the consolidated financial statements of Neurosense Therapeutics Ltd. /s/ Somekh Chaikin Member Fi |
|
| April 7, 2025 |
AMENDED AND RESTATED ARTICLES OF ASSOCIATION NeuroSense Therapeutics LTD. Exhibit 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of NeuroSense Therapeutics LTD. 1. INTERPRETATION 1.1. In these Articles the following terms shall bear the meanings set opposite to them, unless the context otherwise requires: Terms Meanings Articles These Amended and Restated Articles of Association as may be amended from time to time. Auditor As defined under the Companies Law. Board The |
|
| April 7, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroSense Therapeutics Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 |
|
| April 7, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroSense Therapeutics Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 7, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Or Eisenberg, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroSense Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig |
|
| April 7, 2025 |
NeuroSense TherapEutics Ltd. Insider Trading Compliance Policy Effective Date: November 9, 2021 Exhibit 11.1 NeuroSense TherapEutics Ltd. Insider Trading Compliance Policy Effective Date: November 9, 2021 U.S. federal securities laws prohibit trading in the securities of a company while in possession of material nonpublic information and providing material nonpublic information to others so that they can trade. Violating such laws can undermine investor trust, harm the Company’s reputation, |
|
| April 7, 2025 |
Exhibit 4.2 NEUROSENSE THERAPEUTICS LTD. 2018 SHARE INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS ON AUGUST 30, 2022 NEUROSENSE THERAPEUTICS LTD. 2018 SHARE INCENTIVE PLAN 1. Purpose. The purpose of this 2018 Share Incentive Plan (the “Plan”) is to advance the interests of the Company and its shareholders by attracting and retaining the best available personnel for positions of substantial resp |
|
| April 7, 2025 |
DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and are qualified by reference to the amended and restated articles of association, which are filed as an exhibit to this Annual Report on Form 20-F. General Our authorized share capital consists of 90, |
|
| April 7, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroSense Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4 |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996183 |
|
| February 21, 2025 |
NeuroSense Therapeutics Ltd. Up to $2,556,428 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-269306 AMENDMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED AUGUST 16, 2024 (To prospectus dated January 30, 2023) NeuroSense Therapeutics Ltd. Up to $2,556,428 Ordinary Shares This Amendment No. 1 (the “Amendment”) amends and supplements the information in the prospectus supplement, dated August 16, 2024 (the “Prospectus Supplement”), to the prospec |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-79961 |
|
| January 17, 2025 |
PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333 - 284051 5,280,000 Ordinary Shares Up to 3,520,000 Warrants to Purchase up to 3,520,000 Ordinary Shares Up to 1,656,271 Pre-Funded Warrants to Purchase up to 1,656,271 Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder identified in this prospectus under the section “Selling Sharehold |
|
| January 16, 2025 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel January 16, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: NeuroSense Therapeutics Ltd. (CIK 0001875091) Registration Statement No. 333-284051 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: NeuroSense Therapeutics Ltd. |
|
| January 6, 2025 |
Exhibit 99.1 NeuroSense Regains Compliance with Nasdaq’s Minimum Equity Requirement ● NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company re |
|
| January 6, 2025 |
January 6, 2025 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: NeuroSense Therapeutics Ltd. Registration Statement on Form F-3 Filed December 26, 2024 File No. 333-284051 Dear Mr. Gorsky: On behalf of NeuroSense Therapeutics Ltd. (the “Company”), we are writing to |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2025 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| December 26, 2024 |
As filed with the Securities and Exchange Commission on December 26, 2024. F-3 1 ea0226024-f3neurosense.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 26, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translatio |
|
| December 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) NeuroSense Therapeutics Ltd. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| December 23, 2024 |
EX-99.1 2 ea022572501ex99-1neuro.htm PRESS RELEASE, DATED DECEMBER 23, 2024, ENTITLED "NEUROSENSE THERAPEUTICS ENTERS BINDING TERM SHEET TO ADVANCE PRIMEC FOR ALS." Exhibit 99.1 NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS · Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study · Addit |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6 |
|
| December 18, 2024 |
Exhibit 99.1 NeuroSense Provides Business Update and Third Quarter 2024 Financial Results CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-95311 |
|
| December 12, 2024 |
6,600,000 Ordinary Shares Up to 4,400,000 Warrants to Purchase up to 4,400,000 Ordinary Shares PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333 - 283656 6,600,000 Ordinary Shares Up to 4,400,000 Warrants to Purchase up to 4,400,000 Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder identified in this prospectus under the section “Selling Shareholder,” (the “selling shareholder”) of NeuroSense Therapeutics Ltd. (“NeuroSense,” |
|
| December 12, 2024 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel December 12, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: NeuroSense Therapeutics Ltd. (CIK 0001875091) Registration Statement No. 333-283656 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: NeuroSense Therapeutics Ltd |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| December 11, 2024 |
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Exhibit 99.1 NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC ● The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025. ● PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS |
|
| December 9, 2024 |
NRSN / NeuroSense Therapeutics Ltd. / Rimon Gold Assets Ltd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroSense Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M74240108 (CUSIP Number) December 2, 2024 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuan |
|
| December 9, 2024 |
EX-99.1 2 ea022405101ex99-1neuro.htm JOINT FILING UNDERTAKING Exhibit 99.1 JOINT FILING UNDERTAKING The undersigned, who, together, may be deemed to form a group under section 13(d)(3) of the Securities Exchange Act, being authorized thereunto, hereby agree that the Statement on Schedule 13G, dated December 9, 2024, with respect to the ordinary shares, no par value, of NeuroSense Therapeutics, Ltd |
|
| December 6, 2024 |
As filed with the Securities and Exchange Commission on December 6, 2024. As filed with the Securities and Exchange Commission on December 6, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) State of Israel 2834 |
|
| December 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| December 4, 2024 |
Exhibit 99.1 NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC’s Significant Efficacy and Survival Benefits in ALS ● In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates ● Consistent data |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| December 2, 2024 |
PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 2, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 2, 2024, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subje |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| December 2, 2024 |
ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 2, 2024 |
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price Exhibit 99.1 NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with a single investor and |
|
| November 22, 2024 |
Up to 10,000,000 Ordinary Shares NeuroSense Therapeutics Ltd. PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-283338 Up to 10,000,000 Ordinary Shares NeuroSense Therapeutics Ltd. This prospectus relates to the offer and sale of up to 10,000,000 of our ordinary shares, no par value per share, by YA II PN, LTD., or YA or the Selling Shareholder, a Cayman Islands exempt limited partnership. The ordinary shares represented by ordinary shares bei |
|
| November 21, 2024 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel November 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: NeuroSense Therapeutics Ltd. (CIK 0001875091) Registration Statement No. 333-283338 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: NeuroSense Therapeutics Ltd |
|
| November 19, 2024 |
As filed with the Securities and Exchange Commission on November 19, 2024. As filed with the Securities and Exchange Commission on November 19, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) State of Israel 283 |
|
| November 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-95311 |
|
| October 31, 2024 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of October 31, 2024, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and NEUROSENSE THERAPEUTICS LTD., a company incorporated under the laws of the State of Israel (the “Company”). WHEREAS, the parties desire that, upon the terms and sub |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799618 |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799618 |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 28, 2024 |
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission Exhibit 99.1 NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission ● Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success ● Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 24, 2024 |
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Exhibit 99.1 New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced transformativ |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 15, 2024 |
Exhibit 99.1 NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates ● Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 ● Estimated potential market opportunity: peak of $100M to $150M in annual revenue ● Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass., Oct. 15, 20 |
|
| October 9, 2024 |
Exhibit 99.1 NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada · The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% · Company plans to seek approval in additional countries CAMBRIDGE, Mas |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799618 |
|
| October 1, 2024 |
As filed with the Securities and Exchange Commission on September 30, 2024. As filed with the Securities and Exchange Commission on September 30, 2024. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant |
|
| September 30, 2024 |
The accompanying notes are an integral part of the condensed interim financial statements. Exhibit 99.1 NeuroSense Therapeutics Ltd. Condensed Interim Unaudited balance sheets U.S. dollars in thousands June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalent 1,208 2,640 Other receivables 376 236 Restricted deposit 35 40 Total current assets 1,619 2,916 Non-current assets: Property, plant and equipment, net 77 85 Operating right of use assets 123 162 Restricted dep |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| September 30, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in in conformity with United States of America, or U.S. GAAP. Unless otherwise in |
|
| September 24, 2024 |
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule Exhibit 99.1 NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule CAMBRIDGE, Mass., September 24, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained complian |
|
| September 24, 2024 |
Exhibit 99.2 NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s The Company’s intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass., September 24, 2024, - NeuroSense Therapeutics Ltd. (Na |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996 |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 30, 2024 |
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has received a notification letter from the N |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-9531142 |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 16, 2024 |
NeuroSense Therapeutics Ltd. Up to $2,524,437 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-269306 PROSPECTUS SUPPLEMENT (To prospectus dated January 30, 2023) NeuroSense Therapeutics Ltd. Up to $2,524,437 Ordinary Shares We have entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, or Jones, dated August 16, 2024, or the Sales Agreement, relating to the sale of our ordinary shares, no par val |
|
| August 16, 2024 |
Exhibit 10.1 NeuroSense Therapeutics Ltd. Ordinary Shares (no par value per share) Capital on Demand™ Sales Agreement August 16, 2024 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: NeuroSense Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Jon |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| August 7, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 6, 2024, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject |
|
| August 7, 2024 |
ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 1, 2024 |
Exhibit 99.1 NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial 12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy CAMBRIDGE, Mass., August 1 |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| July 9, 2024 |
Exhibit 99.1 NeuroSense’s PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-9531142 ( |
|
| July 1, 2024 |
Exhibit 99.1 NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC’s Potential as a Disease Modifying Drug ● Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo ● Consistent dat |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| June 27, 2024 |
AMENDMENT NO. 1 TO THE NEUROSENSE THERAPEUTICS LTD. ORDINARY SHARES PURCHASE WARRANT June 26, 2024 Exhibit 10.1 AMENDMENT NO. 1 TO THE NEUROSENSE THERAPEUTICS LTD. ORDINARY SHARES PURCHASE WARRANT June 26, 2024 This Amendment No. 1 to the Ordinary Shares Purchase Warrant (the “Amendment”) originally issued by NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”) to Armistice Capital Master Fund Ltd. (the “Investor”) on June 26, 2023 for the purchase of 3,000 |
|
| June 27, 2024 |
AMENDMENT NO. 1 TO THE NEUROSENSE THERAPEUTICS LTD. ORDINARY SHARES PURCHASE WARRANT June 26, 2024 Exhibit 10.2 AMENDMENT NO. 1 TO THE NEUROSENSE THERAPEUTICS LTD. ORDINARY SHARES PURCHASE WARRANT June 26, 2024 This Amendment No. 1 to the Ordinary Shares Purchase Warrant (the “Amendment”) originally issued by NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”) to Armistice Capital Master Fund Ltd. (the “Investor”) on April 15, 2024 for the purchase of 2,98 |
|
| June 27, 2024 |
3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated April 8, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-273375 3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares This prospectus supplement updates, amends and supplements the prospectus dated April 8, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a par |
|
| June 27, 2024 |
Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated May 22, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-279324 Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares This prospectus supplement updates, amends and supplements the prospectus dated May 22, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of o |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| June 24, 2024 |
Exhibit 99.1 NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing novel tr |
|
| June 21, 2024 |
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal Exhibit 99.1 NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal CAMBRIDGE, Mass., June 21, 2024, - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the Com |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| June 17, 2024 |
Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated May 22, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-279324 Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares This prospectus supplement updates, amends and supplements the prospectus dated May 22, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of o |
|
| June 17, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in in accordance with generally accepted accounting principles of the United Stat |
|
| June 17, 2024 |
3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated April 8, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-273375 3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares This prospectus supplement updates, amends and supplements the prospectus dated April 8, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a par |
|
| June 17, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of December 31, 2023 and 2022 F-3 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023, 2022 and 2021 F-4 Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2023 |
|
| June 17, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 99.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-262480) on Form S-8 and (Nos. 333-269306 and 333-260338) on Form F-3 of our report dated June 17, 2024, with respect to the consolidated financial statements of NeuroSense Therapeutics Ltd. Somekh Chaikin Member Firm of KPMG International Tel Av |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 46 |
|
| May 28, 2024 |
Exhibit 99.2 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| May 28, 2024 |
Exhibit 99.1 11 Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual General Meeting of Shareholders (the “Meeting”), of NeuroSense Therapeutics Ltd. (the “Company”), to be held at 11:00 a.m. (Israel time) on June 27, 2024 at our of |
|
| May 23, 2024 |
Exhibit 99.1 11 Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual General Meeting of Shareholders (the “Meeting”), of NeuroSense Therapeutics Ltd. (the “Company”), to be held at 11:00 a.m. (Israel time) on June 27, 2024 at our of |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| May 22, 2024 |
Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-279324 Up to 3,050,964 Ordinary Shares Ordinary Warrants to Purchase up to 2,980,000 Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholders identified in this prospectus under the section “Selling Shareholders,” (each a “selling shareholder” and collectively the “selling shareholders”) o |
|
| May 21, 2024 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel May 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: NeuroSense Therapeutics Ltd. (CIK 0001875091) Registration Statement No. 333-279324 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: NeuroSense Therapeutics Ltd. (th |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024. As filed with the Securities and Exchange Commission on May 20, 2024. Registration No. 333-279324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) St |
|
| May 20, 2024 |
Exhibit 99.1 NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit CAMBRIDGE, Mass., May 20, 2024, - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will be a key presenter at the ALS Drug Develop |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| May 14, 2024 |
Exhibit 99.1 NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PhaseV’s Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense’s Phase 3 Trial CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ - NeuroSense Therapeutics (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024. As filed with the Securities and Exchange Commission on May 10, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) State of Israel 2834 Not |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| May 7, 2024 |
Exhibit 99.1 NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients ● PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients ● Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAMBRIDGE, M |
|
| April 12, 2024 |
FORM OF ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 5 |
|
| April 12, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject |
|
| April 12, 2024 |
[The remainder of this page has been intentionally left blank.] Exhibit 10.1 April 10, 2024 NeuroSense Therapeutics Ltd. Attention: Alon Ben-Noon Building B 11 HaMenofim Street Herzliya 4672562 Dear Mr. Ben-Noon This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve |
|
| April 12, 2024 |
Exhibit 99.1 NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a singl |
|
| April 12, 2024 |
1,732,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,248,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-269306 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 30, 2023) 1,732,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,248,000 Ordinary Shares We are offering on a “reasonable best efforts” basis 1,732,000 ordinary shares, no par value, or the Ordinary Shares. The purchase price of each Ordinary Share is $1.50. We are also of |
|
| April 12, 2024 |
FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Exhibit 4.1 FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD. Warrant Shares: Issue Date: April 15, 2024 THIS PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-7996183 |
|
| April 10, 2024 |
Exhibit 99.1 April 2024 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties . All statements contained in this presentation other than statements of hist |
|
| April 9, 2024 |
Exhibit 99.1 NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics ● NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field ● Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes (“NDEs” |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4 |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4 |
|
| April 5, 2024 |
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update Exhibit 99.1 NeuroSense Announces Year End 2023 Financial Results and Provides Business Update CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update. Corporate Highl |
|
| April 4, 2024 |
NeuroSense Therapeutics Ltd. Compensation Clawback Policy Adopted August, 2023 Exhibit 97.1 NeuroSense Therapeutics Ltd. Compensation Clawback Policy Adopted August, 2023 Purpose The Board of Directors (the “Board”) of NeuroSense Therapeutics Ltd. (the “Company”) has adopted this compensation clawback policy (the “Policy”) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Sectio |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 4, 2024 |
DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and are qualified by reference to the amended and restated articles of association, which are filed as an exhibit to this Annual Report on Form 20-F. General Our authorized share capital consists of 60, |
|
| April 4, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-262480) on Form S-8 and (No. 333-269306) on Form F-3 of our report dated April 3, 2024, with respect to the consolidated financial statements of Neurosense Therapeutics Ltd. /s/ Somekh Chaikin Member Firm of KPMG International Tel Aviv, Israel A |
|
| April 4, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroSense Therapeutics Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 |
|
| April 4, 2024 |
As filed with the Securities and Exchange Commission on April 4, 2024. As filed with the Securities and Exchange Commission on April 4, 2024. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s na |
|
| April 4, 2024 |
As filed with the Securities and Exchange Commission on April 4, 2024. As filed with the Securities and Exchange Commission on April 4, 2024. Registration No. 333-260338 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1 ON FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Reg |
|
| April 4, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Or Eisenberg, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroSense Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig |
|
| April 4, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroSense Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| April 4, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroSense Therapeutics Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 |
|
| February 22, 2024 |
Exhibit 99.1 February 2024 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties . All statements contained in this presentation other than statements of h |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-79961 |
|
| February 13, 2024 |
SC 13G/A 1 ea193576-13ga2gordonneuro.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* NeuroSense Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M74240 108 (CUSIP Number) December 31, 2023 (Date of Event Which Require |
|
| February 13, 2024 |
SC 13G/A 1 ea193567-13ga2bennoonneuro.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) NeuroSense Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M74240 108 (CUSIP Number) December 31, 2023 (Date of Event Which Require |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| February 7, 2024 |
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule Exhibit 99.1 NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule CAMBRIDGE, Mass., February 7, 2024 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the min |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| January 9, 2024 |
Exhibit 99.1 |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| January 9, 2024 |
Exhibit 99.1 NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass., Ja |
|
| December 27, 2023 |
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement Exhibit 99.1 NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement ● This notification has no immediate effect on the listing or trading of NeuroSense’s ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass., December 27, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a company developing treatments for severe n |
|
| December 27, 2023 |
Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated December 4, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. 333-260338 Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants This prospectus supplement updates, amends and supplements the prospectus dated December 4, 2023 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6 |
|
| December 21, 2023 |
Exhibit 99.1 December 2023 Nasdaq: NRSN Forward - Looking Statements 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties . All statements contained in this presentation other than statements of |
|
| December 14, 2023 |
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial Exhibit 99.1 NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial ● A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in-ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysis ● Neurofilament biomarker results from Biogen collaboration expected in Januar |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6 |
|
| December 14, 2023 |
Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated December 4, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. 333-260338 Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants This prospectus supplement updates, amends and supplements the prospectus dated December 4, 2023 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration |
|
| December 5, 2023 |
Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 4, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. 333-260338 Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants This prospectus supplement updates, amends and supplements the prospectus dated December 4, 2023 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration |
|
| December 5, 2023 |
Exhibit 99.2 NeuroSense’s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints ● Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: o PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placebo o Meaningful slowing |
|
| December 5, 2023 |
Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants NeuroSense Therapeutics Ltd. Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-260338 Up to 1,755,000 Ordinary Shares Underlying Previously Issued Warrants NeuroSense Therapeutics Ltd. This prospectus relates to the issuance of up to (i) 1,655,000 of our ordinary shares, no par value per share (the “ordinary shares”) issuable upon the exercise of warrants that were issued as part of an initial public offering ( |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6 |
|
| December 5, 2023 |
Exhibit 99.1 NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023 Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for neurodegenerative |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023. As filed with the Securities and Exchange Commission on December 4, 2023. Registration No. 333-260338 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s |
|
| December 4, 2023 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel December 4, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Lauren Hamill Re: NeuroSense Therapeutics Ltd. Post-Effective Amendment No. 3 to Registration Statement on Form F-1 Filed December 4, 2023 File No. 333-260338 Ladies an |
|
| November 28, 2023 |
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update ● Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 ● Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to conti |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6 |
|
| November 21, 2023 |
As filed with the Securities and Exchange Commission on November 21, 2023. As filed with the Securities and Exchange Commission on November 21, 2023. Registration No. 333-260338 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’ |
|
| November 21, 2023 |
Exhibit 10.2 NEUROSENSE THERAPEUTICS LTD. 2018 SHARE INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS ON AUGUST 30, 2022 NEUROSENSE THERAPEUTICS LTD. 2018 SHARE INCENTIVE PLAN 1. Purpose. The purpose of this 2018 Share Incentive Plan (the “Plan”) is to advance the interests of the Company and its shareholders by attracting and retaining the best available personnel for positions of substantial res |
|
| November 13, 2023 |
Exhibit 99.1 NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness · Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| November 6, 2023 |
Exhibit 99.1 NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 ● Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023 ● Biogen collaboration biomarker results expected Q1 2024 ● Primary biomarker endpoints to be reported H1 2024 CAMBRIDGE, M |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 17, 2023 |
NeuroSense CEO Provides Q3 2023 Update Phase 2b ALS topline results expected December 2023 Exhibit 99.1 NeuroSense CEO Provides Q3 2023 Update Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass., Oct. 17, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during an |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 4, 2023 |
NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model Exhibit 99.1 NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model ● In collaboration with the University of Southern California’s Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing induced pluripotent stem cells (iPSCs) generated from people living with ALS ● Results reinforc |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya |
|
| October 2, 2023 |
Exhibit 99.1 NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024 CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developi |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzli |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| September 20, 2023 |
European Medicines Agency Grants NeuroSense SME Status Exhibit 99.1 European Medicines Agency Grants NeuroSense SME Status ● SME status offers regulatory guidance and engagement in dialogue with EMA ● NeuroSense to open an EU office in Ulm, Germany ● Company plans to enroll patients at multiple sites across Europe in its planned Phase 3 pivotal ALS study of PrimeC CAMBRIDGE, Mass., Sept. 20, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NR |
|
| September 19, 2023 |
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC Exhibit 99.1 NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC ● Patents valid through 2038 ● Clinical topline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that the Eur |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliy |
|
| September 12, 2023 |
Exhibit 99.1 Investor Webinar September 2023 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this presentation other than s |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 562 Israel +972-9-9531142 |
|
| September 7, 2023 |
3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-273375 3,000,000 Ordinary Shares 3,000,000 Ordinary Warrants to purchase up to 3,000,000 Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder identified in this prospectus under the section “Selling Shareholder,” (the “selling shareholder”) of NeuroSense Therapeutics Ltd. (“NeuroSense,” |
|
| August 31, 2023 |
As filed with the Securities and Exchange Commission on August 31, 2023. As filed with the Securities and Exchange Commission on August 31, 2023. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) |
|
| August 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| August 31, 2023 |
NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel August 31, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Cindy Polynice Laura Crotty Re: NeuroSense Therapeutics Ltd. Amendment No. 2 to the Registration Statement on Form F-1 Filed August 31, 2023 File No. 333-273375 Ladies a |
|
| August 16, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in in conformity with International Financial Reporting Standards as issued by th |
|
| August 16, 2023 |
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update ● ALS Phase 2b PARADIGM Trial Completed Patient Enrollment ● Topline results expected in Q-4 2023 ● Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treat |
|
| August 16, 2023 |
The accompanying notes are an integral part of the condensed interim financial statements. Exhibit 99.2 NeuroSense Therapeutics Ltd. Condensed Interim Unaudited Statements of Financial Position U.S. dollars in thousands June 30, December 31, 2023 2022 Assets Current assets: Cash 7,089 3,543 Short term deposits - 3,547 Other receivables 434 255 Restricted deposit 38 36 Total current assets 7,561 7,381 Non-current assets: Property, plant and equipment, net 93 77 Right of use assets 191 22 |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-618 |
|
| August 14, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023. As filed with the Securities and Exchange Commission on August 14, 2023. Registration No. 333-273375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) |
|
| August 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| August 14, 2023 |
Covington & Burling LLP The New York Times Building 620 Eighth Avenue New York, NY 10018-1405 T +12128411000 August 14, 2023 VIA EDGAR U. |
|
| July 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) NeuroSense Therapeutics Ltd. |
|
| July 21, 2023 |
Subsidiaries of NeuroSense Therapeutics Ltd. Exhibit 21.1 Subsidiaries of NeuroSense Therapeutics Ltd. Legal Name Jurisdiction of Incorporation NeuroSense US Inc. Delaware |
|
| July 21, 2023 |
As filed with the Securities and Exchange Commission on July 21, 2023. As filed with the Securities and Exchange Commission on July 21, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) State of Israel 2834 No |
|
| July 6, 2023 |
NeuroSense CEO Provides Q2 2023 Update View video here: Link Exhibit 99.1 NeuroSense CEO Provides Q2 2023 Update View video here: Link CAMBRIDGE, Mass., July 6, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during the second quarter of 2023. Phase 2b Amyotroph |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| June 23, 2023 |
[The remainder of this page has been intentionally left blank.] Exhibit 1.1 June 22, 2023 NeuroSense Therapeutics Ltd. Attention: Alon Ben-Noon Building B 11 HaMenofim Street Herzliya 4672562 Dear Mr. Ben-Noon This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve a |
|
| June 23, 2023 |
1,330,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,670,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-269306 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 30, 2023) 1,330,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,670,000 Ordinary Shares We are offering on a “reasonable best efforts” basis 1,330,000 ordinary shares, no par value (the “Ordinary Shares”). The purchase price of each Ordinary Share is $1.50. We are also of |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 56 |
|
| June 23, 2023 |
FORM OF PRE-FUNDED Ordinary Shares PURCHASE WARRANT NeuroSense Therapeutics Ltd. Exhibit 4.2 FORM OF PRE-FUNDED Ordinary Shares PURCHASE WARRANT NeuroSense Therapeutics Ltd. Warrant Shares: Issue Date: June , 2023 THIS PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| June 23, 2023 |
FORM OF Ordinary Shares PURCHASE WARRANT NeuroSense Therapeutics Ltd. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 23, 2023 |
Exhibit 99.1 NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement CAMBRIDGE, Mass., June 22, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused in |
|
| June 23, 2023 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 22, 2023, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, |
|
| June 22, 2023 |
Up to $502,230 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-269306 PROSPECTUS SUPPLEMENT (To the Prospectus dated April 14, 2023) Up to $502,230 Ordinary Shares This prospectus supplement dated June 22, 2023, or this Prospectus Supplement, supplements the Sales Agreement Prospectus Supplement dated April 14, 2023 that forms a part of our registration statement on Form F-3 (Registration No. 333-269306) t |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 467 |
|
| June 8, 2023 |
Exhibit 99.1 Corporate Presentation June 2023 Nasdaq: NRSN Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Al l s tatements contained in this presentation other than statements of h |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 56 |
|
| June 1, 2023 |
Exhibit 99.1 NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023 CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6183 |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-9531142 (Ad |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number: 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-799-6183 ( |
|
| May 15, 2023 |
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial Exhibit 99.1 NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial · 96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension · Topline results expected Q4 2023 CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative di |
|
| May 2, 2023 |
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson’s Biomarker Study Exhibit 99.1 NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson’s Biomarker Study ● Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson’s disease (PD) compared to healthy individuals ● NeuroSense’s combination platform has been observed in a clinical trial to induce an increase of AGO2 in ALS |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672 |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672 |
|
| April 26, 2023 |
Exhibit 99.2 |
|
| April 26, 2023 |
Exhibit 99.1 11 Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 30, 2023 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual General Meeting of Shareholders (the “Meeting”), of NeuroSense Therapeutics Ltd. (the “Company”), to be held at 11:00 a.m. (Israel time) on May 30, 2023 at our offi |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-41084 NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9-9531142 ( |
